179624-69-2

Upstream product

• 179626-16-5 N-[2,4-dichloro-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)phenyl]-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-methylacetamide 
• 179626-19-8 2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide 
• 179626-56-3 2-methyl-4-(4-morpholinyl)-8-quinolinol 
• 167837-49-2 2,6-dichloro-1-methylsulfonyloxymethyl-3-[N-methyl-N-(phthalimidoacetyl)amino]benzene 
• 167837-48-1 N-(2,4-dichloro-3-(hydroxymethyl)phenyl)-2-(1,3-dioxoisoindolin-2-yl)-N-methylacetamide 
• 28507-46-2 4-chloro-8-hydroxy-2-methylquinoline 
• 179624-53-4 ethyl 5-[(1E)-3-({2-[2,4-dichloro(methyl)-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)anilino]-2-oxoethyl}amino)-3-oxo-1-propenyl]-2-pyridinecarboxylate 

Relevant academic research and scientific papers

A New Class of Nonpeptide Bradykinin B2 Receptor Ligand, Incorporating a 4-Aminoquinoline Framework. Identification of a Key Pharmacophore to Determine Species Difference and Agonist/Antagonist Profile

Introduction of various aliphatic amino groups at the 4-position of the quinoline moiety of our nonpeptide bradykinin (BK) B2 receptor antagonists afforded highly potent ligands for human B2 receptor with various affinities for guine

Quinoline derivatives, processes for their preparation and their use as medicaments

PCT No. PCT/JP97/01415 Sec. 371 Date Oct. 26, 1998 Sec. 102(e) Date Oct. 26, 1998 PCT Filed Apr. 24, 1997 PCT Pub. No. WO97/15877 PCT Pub. Date Apr. 24, 1997A compound of the formula: wherein R1 is lower alkyl, R2 is hydrogen, lower alkyl or a heterocyclic group, R3 is hydrogen, lower alkyl or halogen, R4 is lower alkyl or halogen, R5 is nitro or amino substituted with substituent(s) selected from the group consisting of lower alkyl and acyl, and A is lower alkylene.